Google
Trusted Resources: News & Events
Latest announcements and gatherings
SCA Therapy Hydroxyurea Doesn’t Boost Malaria Risk in Sub-Saharan Africa, Study Finds
Hydroxyurea, a treatment recommended for children with sickle cell anemia (SCA), doesn’t increase the risk of malaria infection in sub-Saharan African countries where malaria is endemic, clearing up previous suspicions, a new study finds.
Sold under the brand names Hydrea (Bristol-Myers Squibb) or Droxia (Bristol-Myers Squibb), hydroxyurea had been previously associated with a reduction in the time to a child’s first malaria episode within the SCA population after treatment. This suggested that doctors should think twice before prescribing hydroxyurea in malaria-endemic regions.
+myBinderRelated Content
-
Sickle Cell Disease Management & Complications: Sophie Lanzkron MD of Johns HopkinsStuck on sickle cell disease? We hammer ...
-
Pneumococcal vaccination coverage among children with sickle cell anemia, sickle cell trait, and normal hemoglobinBackground: Children with sickle cell a...
-
Sickle Cell Treatment Endari Now Available in the United StatesEmmaus Life Sciences has announced that ...
-
Inhaled nitric oxide for acute chest syndrome in adult sickle cell patients: a randomized controlled studyPURPOSE: Previous clinical trials sugges...
-
Sickle Cell Treatments can Destroy Germ Cells in Boys, Affecting Fertility in Adulthood, Study SuggestsSome treatments for sickle cell disease ...
-
Emmaus, a leader in sickle cell disease treatment, signs agreement with McKesson to expand distribution network for ...Emmaus Life Sciences, Inc., anno...
-
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe SCD and Transfusion-Dep...BOSTON & ZUG, Switzerland--(BUSINESS...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.